EBV感染相关淋巴增殖性疾病治疗的研究进展
摘要
EBV感染相关淋巴增殖性疾病是一种EBV感染后T、NK、B细胞异常增殖的综合征,包括传染性单核细胞增多症、慢性活动性EBV感染、EBV相关噬血细胞性淋巴组织细胞增生症、EBV相关淋巴瘤等。此类疾病临床表现复杂多样,治疗困难,预后较差。传染性单核细胞增多症的主要治疗方法是支持治疗和抗病毒治疗,病毒疫苗正在研发当中。慢性活动性EBV感染的治疗手段包括抗病毒治疗、免疫调节治疗、造血干细胞移植、EBV特异性细胞毒性T淋巴细胞治疗、基因靶向治疗,目前尚无统一有效的治疗方案。EBV相关噬血细胞性淋巴组织细胞增生症主要采用免疫化疗方案及大剂量激素冲击治疗、大剂量丙种球蛋白冲击治疗等。EBV相关淋巴瘤的主要治疗方案为化疗,也可使用自体T细胞疗法联合PD-L1抑制剂治疗。
引文
[1]Cohen JI,Jaffe ES,Dale JK,et al.Characterization and treatment of chronic active Epstein-Barr virus disease:a 28-year experience in the United States[J].Blood,2011,117(22):5835-5849.
[2]Bazot Q,Paschos K,Allday MJ.Epstein-Barr Virus(EBV)latent protein EBNA3A directly targets and silences the STK39 gene in Bcells infected by EBV[J].J Virol,2018,92(7):e1918.
[3]Worth AJ,Houldcroft CJ,Booth C.Severe Epstein-Barr virus infection in primary immunodeficiency and the normal host[J].Br JHaematol,2016,175(4):559-576.
[4]Allday MJ,Bazot Q,White RE.The EBNA3 Family:Two Oncoproteins and a Tumour Suppressor that Are Central to the Biology of EBVin B Cells[J].Curr Top Microbiol Immunol,2015,391:61-117.
[5]Styles CT,Bazot Q,Parker GA,et al.EBV epigenetically suppresses the B cell-to-plasma cell differentiation pathway while establishing long-term latency[J].PLo S Biol,2017,15(8):e2001992.
[6]Fitzsimmons L,Kelly GL.EBV and Apoptosis:The Viral Master Regulator of Cell Fate[J].Viruses,2017,9(11):339.
[7]Luzuriaga K,Sullivan JL.Infectious mononucleosis[J].N Engl JMed,2010,362(21):1993-2000.
[8]Balfour HH Jr,Odumade OA,Schmeling DO,et al.Behavioral,virologic,and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students[J].J Infect Dis,2013,207(1):80-88.
[9]Yager JE,Magaret AS,Kuntz SR,et al.Valganciclovir for the suppression of epstein-barr virus replication[J].J Infect Dis,2017,216(2):198-202.
[10]Rezk E,Nofal YH,Hamzeh A,et al.Steroids for symptom control in infectious mononucleosis[J].Cochrane Database Syst Rev,2015,11:Cd004402.
[11]Ghosal R,Lewis KE,Chandramouli S.Infectious mononucleosis complicated by acute hepatitis and myocarditis:a response to corticosteroids[J].BMJ Case Rep,2009,4:1083.
[12]Kawamoto K,Miyoshi H,Suzuki T,et al.A distinct subtype of Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorder:adult patients with chronic active Epstein-Barr virus infection-like features[J].Haematologica,2018,103(6):1018-1028.
[13]Arai A.Chronic active Epstein-Barr virus infection:a bi-faceted disease with inflammatory and neoplastic elements[J].Immunol Med,2018,41(4):162-169.
[14]Ai J,Xie Z.Epstein-barr virus-positive T/NK-cell lymphoproliferative diseases in Chinese mainland[J].Front Pediatr,2018,6:289.
[15]Arai A,Sakashita C,Hirose C,et al.Hematopoietic stem cell transplantation for adults with EBV-positive T-or NK-cell lymphoproliferative disorders:efficacy and predictive markers[J].Bone Marrow Transplant,2016,51(6):879-882.
[16]Hui KF,Yiu SPT,Tam KP,et al.Viral-targeted strategies against EBV-associated lymphoproliferative diseases[J].Front Oncol,2019,9:81.
[17]Marsh RA.Epstein-barr virus and hemophagocytic lymphohistiocytosis[J].Front Immunol,2018,8:1902.
[18]Bergsten E,Horne A,Arico M,et al.Confirmed efficacy of etoposide and dexamethasone in HLH treatment:long-term results of the cooperative HLH-2004 study[J].Blood,2017,130(25):2728-2738.
[19]Marsh RA,Jordan MB,Talano JA,et al.Salvage therapy for refractory hemophagocytic lymphohistiocytosis:a review of the published experience[J].Pediatr Blood Cancer,2017,64(4):e26308.
[20]Oyama T,Yamamoto K,Asano N,et al.Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group:a study of 96 patients[J].Clin Cancer Res,2007,13(17):5124-5132.
[21]Hoeller S,Tzankov A,Pileri SA,et al.Epstein-Barr virus-positive diffuse large B-cell lymphoma in elderly patients is rare in western populations[J].Hum Pathol,2010,41(3):352-357.
[22]Camicia R,Winkler HC,Hassa PO.Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma:a comprehensive review[J].Mol Cancer,2015,14:207.
[23]Dotan E,Aggarwal C,Smith MR.Impact of rituximab(rituxan)on the treatment of B-cell non-Hodgkin's lymphoma[J].P T,2010,35(3):148-157.
[24]Zhang M,Xu-monette ZY,Li L,et al.Rel A NF-kappaB subunit activation as a therapeutic target in diffuse large B-cell lymphoma[J].Aging,2016,8(12):3321-3340.
[25]Ramos CA,Heslop HE,Brenner MK.CAR-T cell therapy for lymphoma[J].Annu Rev Med,2016,67:165-183.
[26]Wang Z,Wu Z,Liu Y,et al.New development in CAR-T cell therapy[J].J Hematol Oncol,2017,10(1):53.
[27]Kwon D,Kim S,Kim PJ,et al.Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas[J].Histopathology,2016,68:1079-1089.
[28]Gravelle P,Burroni B,Pericart S,et al.Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma:a summary of immunohistochemical studies[J].Oncotarget,8(27):44960-44975.
[29]Weiss ER,Alter G,Ogembo JG,et al.High epstein-barr virus load and genomic diversity are associated with generation of gp350-specific neutralizing antibodies following acute infectious mononucleosis[J].JVirol,2017,91(1):e01562.
[2]Bazot Q,Paschos K,Allday MJ.Epstein-Barr Virus(EBV)latent protein EBNA3A directly targets and silences the STK39 gene in Bcells infected by EBV[J].J Virol,2018,92(7):e1918.
[3]Worth AJ,Houldcroft CJ,Booth C.Severe Epstein-Barr virus infection in primary immunodeficiency and the normal host[J].Br JHaematol,2016,175(4):559-576.
[4]Allday MJ,Bazot Q,White RE.The EBNA3 Family:Two Oncoproteins and a Tumour Suppressor that Are Central to the Biology of EBVin B Cells[J].Curr Top Microbiol Immunol,2015,391:61-117.
[5]Styles CT,Bazot Q,Parker GA,et al.EBV epigenetically suppresses the B cell-to-plasma cell differentiation pathway while establishing long-term latency[J].PLo S Biol,2017,15(8):e2001992.
[6]Fitzsimmons L,Kelly GL.EBV and Apoptosis:The Viral Master Regulator of Cell Fate[J].Viruses,2017,9(11):339.
[7]Luzuriaga K,Sullivan JL.Infectious mononucleosis[J].N Engl JMed,2010,362(21):1993-2000.
[8]Balfour HH Jr,Odumade OA,Schmeling DO,et al.Behavioral,virologic,and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students[J].J Infect Dis,2013,207(1):80-88.
[9]Yager JE,Magaret AS,Kuntz SR,et al.Valganciclovir for the suppression of epstein-barr virus replication[J].J Infect Dis,2017,216(2):198-202.
[10]Rezk E,Nofal YH,Hamzeh A,et al.Steroids for symptom control in infectious mononucleosis[J].Cochrane Database Syst Rev,2015,11:Cd004402.
[11]Ghosal R,Lewis KE,Chandramouli S.Infectious mononucleosis complicated by acute hepatitis and myocarditis:a response to corticosteroids[J].BMJ Case Rep,2009,4:1083.
[12]Kawamoto K,Miyoshi H,Suzuki T,et al.A distinct subtype of Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorder:adult patients with chronic active Epstein-Barr virus infection-like features[J].Haematologica,2018,103(6):1018-1028.
[13]Arai A.Chronic active Epstein-Barr virus infection:a bi-faceted disease with inflammatory and neoplastic elements[J].Immunol Med,2018,41(4):162-169.
[14]Ai J,Xie Z.Epstein-barr virus-positive T/NK-cell lymphoproliferative diseases in Chinese mainland[J].Front Pediatr,2018,6:289.
[15]Arai A,Sakashita C,Hirose C,et al.Hematopoietic stem cell transplantation for adults with EBV-positive T-or NK-cell lymphoproliferative disorders:efficacy and predictive markers[J].Bone Marrow Transplant,2016,51(6):879-882.
[16]Hui KF,Yiu SPT,Tam KP,et al.Viral-targeted strategies against EBV-associated lymphoproliferative diseases[J].Front Oncol,2019,9:81.
[17]Marsh RA.Epstein-barr virus and hemophagocytic lymphohistiocytosis[J].Front Immunol,2018,8:1902.
[18]Bergsten E,Horne A,Arico M,et al.Confirmed efficacy of etoposide and dexamethasone in HLH treatment:long-term results of the cooperative HLH-2004 study[J].Blood,2017,130(25):2728-2738.
[19]Marsh RA,Jordan MB,Talano JA,et al.Salvage therapy for refractory hemophagocytic lymphohistiocytosis:a review of the published experience[J].Pediatr Blood Cancer,2017,64(4):e26308.
[20]Oyama T,Yamamoto K,Asano N,et al.Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group:a study of 96 patients[J].Clin Cancer Res,2007,13(17):5124-5132.
[21]Hoeller S,Tzankov A,Pileri SA,et al.Epstein-Barr virus-positive diffuse large B-cell lymphoma in elderly patients is rare in western populations[J].Hum Pathol,2010,41(3):352-357.
[22]Camicia R,Winkler HC,Hassa PO.Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma:a comprehensive review[J].Mol Cancer,2015,14:207.
[23]Dotan E,Aggarwal C,Smith MR.Impact of rituximab(rituxan)on the treatment of B-cell non-Hodgkin's lymphoma[J].P T,2010,35(3):148-157.
[24]Zhang M,Xu-monette ZY,Li L,et al.Rel A NF-kappaB subunit activation as a therapeutic target in diffuse large B-cell lymphoma[J].Aging,2016,8(12):3321-3340.
[25]Ramos CA,Heslop HE,Brenner MK.CAR-T cell therapy for lymphoma[J].Annu Rev Med,2016,67:165-183.
[26]Wang Z,Wu Z,Liu Y,et al.New development in CAR-T cell therapy[J].J Hematol Oncol,2017,10(1):53.
[27]Kwon D,Kim S,Kim PJ,et al.Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas[J].Histopathology,2016,68:1079-1089.
[28]Gravelle P,Burroni B,Pericart S,et al.Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma:a summary of immunohistochemical studies[J].Oncotarget,8(27):44960-44975.
[29]Weiss ER,Alter G,Ogembo JG,et al.High epstein-barr virus load and genomic diversity are associated with generation of gp350-specific neutralizing antibodies following acute infectious mononucleosis[J].JVirol,2017,91(1):e01562.